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Abstract
Background: The aims of this systematic review are to (a) evaluate the current literature on the impact of postoperative therapy for resected squamous
cell carcinoma of the head and neck (SCCHN) on oncologic and non-oncologic
outcomes and (b) identify the optimal evidence-based postoperative therapy
recommendations for commonly encountered clinical scenarios.
Methods: An analysis of the medical literature from peer-reviewed journals
was conducted using the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) guideline. Prospective studies and methodologybased systematic reviews and meta-analyses of postoperative therapy for
SCCHN were identified by searching Medline (OVID) and EMBASE (Elsevier)

The American Radium Society Appropriate Use Criteria and its expert panels have developed criteria for determining appropriate procedures for
diagnosis and treatment of specified medical condition(s). These criteria are intended to guide treating and referring physicians in making decisions
regarding diagnosis and treatment of cancers and related or associated conditions. Generally, the complexity and severity of a patient's clinical
condition should dictate the selection of appropriate diagnostic procedures or treatments. Only those examinations or treatments generally used for
evaluation of the patient's condition are ranked. Other procedures necessary to evaluate or treat other co-existent diseases or other medical
consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of
appropriate procedures or treatments. Procedures, techniques, or other interventions classified as investigational by the FDA have not been
considered in developing these criteria; however, study of new equipment, applications, and treatment protocols should be encouraged. The ultimate
decision regarding the appropriate use of any specific examination or treatment must be made by the referring physician and oncologist in light of all
the circumstances presented in an individual examination. The ARS Appropriate Use Criteria seek and encourage collaboration with other
organizations on the development of the Criteria through representation on expert panels. Participation by representatives from collaborating
organizations on the expert panel does not necessarily imply individual or society endorsement of the final document. The opinions or assertions
contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Uniformed Services
University of the Health Sciences or the Department of Defense or the National Institutes of Health.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. Head & Neck published by Wiley Periodicals LLC.
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using controlled vocabulary terms (ie, National Library of Medicine Medical
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Subject Headings [MeSH], EMTREE). Study screening and selection was per-
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formed with Covidence software and full-text review. The RAND/UCLA
appropriateness method was used by the expert panel to rate the appropriate
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use of postoperative therapy, and the modified Delphi method was used to
come to consensus.
Results: A total of 5660 studies were identified and screened using the title
and abstract, leading to 201 studies assessed for relevance using full-text
review. After limitation to the eligibility criteria, 101 studies from 1977 to 2020
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were identified, including 77 with oncologic endpoints and 24 with function
and quality of life endpoints. All studies reported staging prior to the implementation of American Joint Committee on Cancer (AJCC-8).
Conclusions: Prospective clinical studies and systematic reviews identified
through the PRISMA systematic review provided good evidence for consensus
statements regarding the appropriate use of postoperative therapy for resected
SCCHN. Further research is needed in domains where consensus by the expert
panel could not be achieved for the appropriateness of specific postoperative
therapeutic interventions.
KEYWORDS
adjuvant therapy, appropriate use, guidelines, head and neck cancer, postoperative

1 | INTRODUCTION
There have been substantial changes in the management
of squamous cell carcinoma of the head and neck
(SCCHN) since publication of the clinical studies that
form the basis of postoperative management for resected
SCCHN. First, the epidemiology, causative factors, and
prognosis of SCCHN have changed, particularly in the
USA and regions of Europe. Oropharyngeal cancers may
not only be caused by cigarette smoking and alcohol consumption but may be virally induced. It has been
established that human papillomavirus (HPV)-mediated
oropharyngeal cancer has an improved prognosis compared to HPV-negative oropharyngeal cancer.1,2 Second,
treatments themselves have evolved. The common clinical use of intensity modulated radiation therapy (IMRT)
facilitates flexibility of radiation targeting. The use of
transoral laser and transoral robotic surgery (TORS) has
increased over the last decade, allowing for less morbid
surgical approaches in the head and neck.3 Third, modern radiologic imaging allows more accurate and sensitive preoperative staging. Lastly, the prognostic power of
additional pathologic risk factors such as depth of invasion (DOI) for oral cavity tumors,4,5 and extranodal
extension (ENE) have been incorporated into the American Joint Committee on Cancer (AJCC) 8th edition

staging classification.6 While changes in staging do not
themselves constitute changes in management, they provide prognostic information and potential additional criterion for eligibility criteria in future clinical trials.
The aims of this systematic review were to
(a) evaluate the current literature on the impact of postoperative therapy for SCCHN on oncologic and nononcologic outcomes and (b) identify the optimal
evidence-based postoperative therapy recommendations
for commonly encountered clinical scenarios. The primary objective was to identify studies with quantitative
outcomes after postoperative radiation therapy (PORT),
postoperative radiation with chemotherapy (chemoPORT), or postoperative chemotherapy with endpoints of
overall survival (OS), and local, regional, and distant control. The secondary objective was to identify studies that
describe quantitative outcomes related to toxicity, quality
of life (QOL), or measurements of function.

2 | METHODS
The American Radium Society (ARS) Appropriate Use
Criteria presented in this manuscript are evidence-based
guidelines for postoperative treatment of squamous cell
carcinoma of the head and neck (SCCHN). Since the ARS
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and the American College of Radiology (ACR) last published a literature review and expert consensus guideline
on postoperative therapy in 2011,7 additional relevant
clinical trials have been published. The objectives of this
systematic review are 2-fold: first, to comprehensively
evaluate existing prospective clinical studies of postoperative therapy for resected SCCHN using a formalized methodologic approach described by the Preferred Reporting
Items for Systematic Review and Meta-Analyses Protocol
(PRISMA-P),8 and second, to provide general treatment
recommendations to assist clinical decision-making,
highlighting areas of controversy and uncertainty.
The literature was reviewed for quality of study
design, cohort size, selection bias, evaluation of participants in relation to time from exposure, and methods of
assessments. The RAND/UCLA appropriateness method9
was used by the expert panel to rate the appropriate use
of procedures and the modified Delphi10 was used to
come to consensus. The expert panel is composed of multidisciplinary radiation, medical, surgical oncologists, and
an academic librarian.

2.1 | Systematic review strategy
An analysis of the medical literature from peer-reviewed
journals was conducted using the Preferred Reporting
Items for Systematic Reviews and Meta-analyses
(PRISMA)8,11 guidelines to search and retrieve a comprehensive set of relevant articles. Studies discussing adjuvant
therapy following surgery for squamous cell carcinoma of
the head and neck were identified by searching Medline
(OVID) and EMBASE (Elsevier) on January 10, 2019. Controlled vocabulary terms (ie, National Library of Medicine
Medical Subject Headings [MeSH], EMTREE) were
included when available and appropriate. The search strategies were designed and executed by a librarian (CM). No
language limits or year restrictions were applied. The exact
search terms used for each of the databases are provided
in the Supporting Information.

2.2 | Study selection
Selection was performed using Covidence software. Title
and abstract screening were performed by one author
(DNM) using the PICO (participants, interventions, comparators, outcomes) inclusion and exclusion criteria outlined below. Full text was obtained for all titles/abstracts
that met inclusion criteria and for studies where there
was uncertainty based on the title/abstract screening.
Full text review was performed by two independent
reviewers (DNM, AGS) blinded to each other's judgment.

3

Disagreement was resolved through discussion regarding
study relevance related to the inclusion/exclusion criteria
and concordance was obtained. Each study was graded
using the Oxford Centre for Evidence-Based Medicine
2011 Levels of Evidence Table.12
The PICO framework was used to identify relevant
studies.8 Studies were included if they were published
randomized controlled trials (RCT), randomized trials,
single and multi-arm non-randomized prospective clinical trials, systematic reviews and meta-analyses that
adhered to a published methodology such as Cochrane
Review, PRISMA, or QUOROM guidelines.13 Longitudinal prospective cohort studies were included only if there
was a baseline pre-intervention assessment. Studies comparing postoperative vs definitive therapy were not
included as this was not the primary objective of the systematic review. The study population included adult
patients (age 18 years or older) with stage I-IVB SCCHN
and no distant metastases (DM), who had no prior head
and neck RT and were treated with curative-intent surgery. The following disease sites were included: oral cavity, oropharynx, hypopharynx, and larynx. Studies were
excluded if they did not include at least 20 patients
treated with surgery and postoperative therapy or the
population was predominantly composed of nasopharyngeal carcinoma, paranasal sinus cancer, cancer of
unknown primary, nasal cavity cancer, recurrent head
and neck cancer, or patients treated with re-irradiation
with or without chemotherapy. Details of the PICO specifications are provided in the Supporting Information.

2.3 | Consensus voting
Clinical variants with corresponding treatment options
were created to represent commonly encountered clinical
scenarios, including those for which management is controversial (Tables 1-3). These were reviewed by all panelists
prior to voting. Variants were circulated for voting
whereby panelists rated each treatment using a score of “1
to 9,” representing “usually not appropriate” (1-3), “may be
appropriate (4-6), and “usually appropriate” (7-9). Panelists
were blinded to each other's votes. The results were
reviewed and discussed, maintaining anonymity of voting.
A second round of voting was performed, and results
were again reviewed and discussed prior to finalizing votes.
The median score was determined and agreement was
determined as per the BIOMED Concerted Action on
Appropriateness definition outlined in the RAND/UCLA
methodology9 whereby agreement was defined as ≤3
votes outside the 3-point region containing the median
(1-3;4-6;7-9), for a panel of 11 to 13, and ≤4 votes outside
the 3-point region containing the median for a panel of

4
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TABLE 1A
Variant 1:

Clinical condition: Resected early-stage SCC of the oral cavity with deep depth of invasion (DOI)

pT2 N0 M0 moderately differentiated SCC of the right lateral oral tongue treated with a partial glossectomy and ipsilateral neck dissection (levels IA-B,
II, III, IV). Pathology showed a 1.5 cm SCC, 1.5 cm DOI, closest margin of 0.5 cm, 24 negative lymph nodes, no perineural invasion or
lymphovascular invasion.

Question 1: Is DOI a factor that prompts any additional therapy?
Treatment

Rating Category

Group Median Rating

Disagreement
X

SOE
L

SOR
—

Observation (No additional therapy)

M*

5

Contralateral neck dissection—no postoperative therapy if pN0

U

2

EC

"

PORT

A

7

EO

—

PORT + concurrent systemic therapy

U

1

EC

"

Question 2: If postoperative RT is administered, what volume is appropriate?
Radiation volume

Rating category

PORT to primary site only

U

Group median rating

Disagreement

3

SOE

SOR

EC

"

PORT to primary site + ipsilateral neck

M*

5

X

EO

—

PORT to primary site + bilateral necka

M*

5

X

EO

—

Notes: Rating: A-Usually appropriate; M-May be appropriate; U-Usually not appropriate. Disagreement, that is, the variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation (see narrative text). When there was disagreement, the group median rating is set automatically to 5. Strength of Evidence: S-Strong; M-Moderate; L-Limited; EC-Expert
consensus; EO-Expert opinion. Strength of Recommendation: " Strong Recommendation; # Weak Recommendation; — Additional considerations do not strengthen or weaken the panel's recommendation.
Abbreviations: DOI, depth of invasion; PORT, postoperative radiation therapy; SCC, squamous cell carcinoma of the head and neck.
a
For this specific variant, “bilateral neck” refers to RT of any contralateral nodal region including contralateral level IB-alone. Of note, these
variants do not provide granularity regarding specific nodal chains of treatment.

TABLE 1B
Variant 2:

Clinical condition: Resected early-stage SCC of the oral cavity with a close margin.

pT2 N0 M0 moderately differentiated SCC of the right lateral oral tongue treated with a partial glossectomy and ipsilateral neck dissection (levels IA-B,
II, III, IV). Pathology showed a 2.5 cm SCC, 0.4 cm depth of invasion, <0.1 cm deep margin, 24 negative lymph nodes, no perineural invasion or
lymphovascular invasion.

Question 1: What additional therapy is recommended for the close margin?
Treatment

Rating Category

Observation (No additional therapy)

U

Group Median Rating
2

Re-excision and no additional therapy if no residual SCC

M*

5

PORT alone 60 to 66 Gy

A

7

PORT alone altered fractionationa

M*

5

PORT conventional fractionationb + systemic therapy

M*

Disagreement

SOE

X

SOR

L

"

L

"

L

"

X

L

—

5

X

L

—

Group median rating

Disagreement

SOE

Question 2: If radiation is recommended, what volumes are appropriate?
Treatment

Rating category

SOR

Radiation volume
PORT to primary site only

M*

5

X

L

—

PORT to primary site + ipsilateral neck

M*

5

X

L

—

PORT to primary site + bilateral neckc

M*

5

X

L

—

Notes: Rating: A-Usually appropriate; M-May be appropriate; U-Usually not appropriate. Disagreement, that is, the variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation (see narrative text). When there was disagreement, the group median rating was set automatically to 5. Strength of Evidence: S-Strong; M-Moderate; L-Limited; EC-Expert
consensus; EO-Expert opinion. Strength of Recommendation: " Strong Recommendation; # Weak Recommendation; — Additional considerations do not strengthen or weaken the panel's recommendation.
Abbreviations: PORT, postoperative radiation therapy; SCC, squamous cell carcinoma of the head and neck; RT, Radiation Therapy.
a
Altered fractionation refers to >2.0 Gy per fraction and/or >5 fractions per week. This excludes the practice of simultaneous integrated
boost of >2.0 Gy per fraction to a limited high-risk area.
b
Conventional fractionation refers to 1.8 to 2.0 Gy per fraction, given once daily, 5 days per week.
c
For this specific variant, “bilateral neck” refers to RT of any contralateral nodal region including contralateral level IB. Of note, these guidelines do not provide granularity regarding specific nodal chains of treatment.
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TABLE 2A
Variant 3:

5

Clinical condition: Resected locally advanced SCC of the larynx with extranodal extension (ENE)

pT3 N2a M0 moderately differentiated SCC of the supraglottic larynx treated with total laryngectomy and bilateral neck dissections (levels II-IV).
Pathology showed a 4.5 cm SCC and a 0.5 cm closest margin. The right neck dissection showed 1 out of 22 left neck nodes with 1.5 cm of SCC from
level II with 2 mm of ENE; the left neck dissection showed 0 involved out of 19 neck nodes.

Question 1: What postoperative therapy is recommended in the presence of ENE?
Treatment

Rating category

Group median rating

Disagreement

SOE

SOR

Observation (No additional therapy)

U

1

S

"

PORT-alone

M*

5

X

S

"

M*

5

X

M

—

A

8

S

"

PORT-alone altered fractionationa
b

PORT conventional fractionation + systemic therapy
Question 2: What are appropriate radiation volumes?
Radiation volume

Rating category

PORT to primary site + bilateral neck

A

Group median rating
8

Disagreement

SOE

PORT to primary site + pathological node-positive neck only

M*

5

PORT to bilateral neck (no primary site)

U

3

PORT to pathological node-positive neck only

U

3

L

"

Rating category

Group median rating

X

SOR

M

"

M

#

L

"

Question 3: Which systemic therapy is appropriate?
Systemic therapy

Disagreement

SOE

SOR

No systemic therapy

U

2

S

"

Cisplatin 100 mg/m2 for 2 to 3 cycles

A

9

S

"

Cisplatin 40 mg/m2 weekly

M*

5

X

L

"

Carboplatin AUC2 weekly

M*

5

X

L

—

Carboplatin AUC2 + paclitaxel weekly

M*

5

X

L

—

Cetuximab weekly

M*

5

X

L

—

Cetuximab + docetaxel 15 mg/m2 weekly

M*

5

X

M

—

Notes: Rating: A-Usually appropriate; M-May be appropriate; U-Usually not appropriate. Disagreement, that is, the variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation (see narrative text). When there was disagreement, the group median rating is set automatically to 5. Strength of Evidence: S-Strong; M-Moderate; L-Limited; EC-Expert
consensus; EO-Expert opinion. Strength of Recommendation: " Strong Recommendation; # Weak Recommendation; — Additional considerations do not strengthen or weaken the panel's recommendation.
a
Altered fractionation refers to >2.0 Gy per fraction and/or >5 fractions per week. This excludes the practice of simultaneous integrated
boost of >2.0 Gy per fraction to a limited high-risk area.
b
Conventional fractionation refers to 1.8 to 2.0 Gy per fraction, given once daily, 5 days per week.

14 to 16. Detailed voting results for the variant Tables 1-3
are provided in the Supporting Information. The strength of
recommendations was graded using the GRADE system.14
Select retrospective studies are referenced only to provide context for specific topics but are not included in the
evidence Tables or as the supporting evidence for oncologic intervention. Such studies are also described as retrospective in the body of the text.

3 | R E SUL T S
3.1 | Characteristics of studies identified
in the literature search
The process of study identification is summarized in
Figure 1. A total of 5689 studies were identified using
Ovid Medline and Embase. After removal of duplicates,

5660 studies were screened using the title and abstract
leading to 201 studies assessed for relevance using fulltext review. After limitation to the eligibility criteria,
96 studies were identified. An additional five eligible
studies were added, including four that were published
after the cut-off date of 01/10/201915-18 and one randomized trial that was not identified through the literature
search.19
Studies with primary oncologic endpoints are shown
in Table S1 and included 11 systematic reviews,20-30 24 randomized trials with four long-term updates,19,31-57 29 nonrandomized clinical trials,15-18,58-82 and nine post hoc analyses of randomized trials.83-91 The randomized trials are
presented in Table 4. Studies that focused on nononcologic endpoints are shown in Table S2 and included
two systematic reviews,92,93 one randomized trial,94 and
21 non-randomized clinical trials.95-115 All studies reported
staging prior to the implementation of AJCC-8.

6
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TABLE 2B
Variant 4:

Clinical condition: Resected locally advanced SCC of the larynx with intermediate risk factors

pT3 N2a M0 moderately differentiated SCC of the supraglottic larynx treated with total laryngectomy and bilateral neck dissections (levels II-IV).
Pathology showed a 4.5 cm SCC with perineural invasion (PNI) and lymphovascular invasion (LVI); 0.5 cm closest margin. The right neck dissection
showed 1 out of 22 left neck nodes with 3.5 cm of SCC from level II without extranodal extension; the left neck dissection showed 0 out of 19
involved neck nodes.

Question 1: What postoperative therapy is recommended in the presence of multiple intermediate risk factors?
Treatment

Rating category

Observation (No additional therapy)

U

Group median rating

Disagreement

SOE

2

S

SOR
"

PORT-alone 60 to 66 Gy

A

8

M

"

PORT-alone altered fractionationa

M*

5

X

M

#

PORT conventional fractionationb + systemic therapy

M*

5

X

M

#

Notes: Rating: A-Usually appropriate; M-May be appropriate; U-Usually not appropriate. Disagreement, that is, the variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation (see narrative text). When there was disagreement, the group median rating was set automatically to 5. Strength of Evidence: S-Strong; M-Moderate; L-Limited; EC-Expert
consensus; EO-Expert opinion. Strength of Recommendation: " Strong Recommendation; # Weak Recommendation; — Additional considerations do not strengthen or weaken the panel's recommendation.
a
Altered fractionation refers to >2.0 Gy per fraction and/or >5 fractions per week. This excludes the practice of simultaneous integrated
boost of >2.0 Gy per fraction to a limited high-risk area.
b
Conventional fractionation refers to 1.8 to 2.0 Gy per fraction, given once daily, 5 days per week.

TABLE 3A
Variant 5:

Clinical condition: Resected p16-positive SCC of the oropharynx

A lifetime non-smoker with a pT1 N1 M0 p16-positive SCC of the tonsil treated with transoral radical resection and ipsilateral neck dissection (levels IIIV). The pathology showed a 1.5 cm tonsil-confined tumor, 0.5 cm closest margin. There were 1 of 22 nodes with a 4.0 cm deposit of SCC at level II
with no extranodal extension.

Question 1: What additional therapy is recommended in the presence of a single involved lymph node > 3 cm?
Treatment

Rating Category

Group Median Rating

Disagreement

SOE

SOR

Observation (No additional therapy)

M*

5

X

EO

—

PORT alone, de-escalation 50 to 54 Gy

M*

5

X

EC

#

PORT-alone, 60 to 66 Gy

A

7

L

#

U

1

EC

"

a

PORT conventional fractionation + systemic therapy

Question 2: If PORT is recommended what are appropriate treatment volumes?
Treatment radiation volume

Rating category

PORT to primary site + ipsilateral neck

A

Group median rating
8

PORT to primary site + bilateral neck

M*

5

PORT to ipsilateral neck only

M*

5

Disagreement

SOE

SOR

M

"

X

L

—

X

EC

—

Notes: Rating: A-Usually appropriate; M-May be appropriate; U-Usually not appropriate. Disagreement, that is, the variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation (see narrative text). When there was disagreement, the group median rating was set automatically to 5. Strength of Evidence: S-Strong; M-Moderate; L-Limited; EC-Expert
consensus; EO-Expert opinion. Strength of Recommendation: " Strong Recommendation; # Weak Recommendation; — Additional considerations do not strengthen or weaken the panel's recommendation.
a
Conventional fractionation refers to 1.8 to 2.0 Gy per fraction, given once daily, 5 days per week.

4 | TOPIC 1 : SUMMARY OF
S T U D I E S WI T H ON C O L O G I C
ENDPOINTS
4.1 | The role of postoperative radiation
therapy (PORT)
There are two randomized trials comparing observation to PORT. One trial showed a disease-free survival

(DFS) benefit with PORT for patients with stage III/IV
buccal mucosa cancers.45 The other randomized trial
demonstrated a non-statistically significant difference
in overall recurrence (55.6% vs 36.5%, P = NS, exact
value not reported).41 Single arm phase I and phase II
studies showed that PORT can be sequenced after minimally invasive surgery including transoral laser supraglottic laryngectomy,58 and transoral robotic
surgery.62,69,82
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TABLE 3B
Variant 6:

7

Clinical condition: Resected p16-positive SCC of the oropharynx with extranodal extension (ENE).

A lifetime non-smoker with a pT1 N1 M0 p16-positive SCC of the tonsil treated with transoral radical resection and ipsilateral neck dissection (levels IIIV). The tumor was 1.5 cm, tonsil-confined, with a 0.5 cm closest margin. The ipsilateral neck dissection showed 1 out of 22 left neck nodes with a
4.0 cm SCC deposit at level II with 0.2 cm ENE.

Question 1: In the presence of ENE, what postoperative therapy is recommended?
Treatment

Rating category

Group median rating

Observation (No additional therapy)

U

PORT alone, de-escalation 50 to 54 Gy

U

PORT alone, 60 to 66 Gy

M*

5

PORT conventional fractionationa + systemic therapy

A

8

Disagreement

SOE

SOR

1

EC

"

2

M

"

M

—

M

#

X

Question 2: What radiation volume is appropriate?
Treatment radiation volume

Rating category

PORT to primary site + ipsilateral neck

A

Group median rating
7

PORT to primary site + bilateral neck

A

7

PORT to ipsilateral neck only

M*

5

Disagreement

X

SOE

SOR

EC

"

EC

#

EO

—

Question 3: What concurrent systemic therapy is appropriate, if recommended?
Treatment radiation volume

Rating category

Group median rating

Disagreement
X

M

#
"

X

L

"

5

X

L

"

5

X

EC

—

M*

5

X

EC

—

M*

5

X

EO

"

M*

5

Cisplatin 100 mg/m2 for 2 to 3 cycles

A

8

Cisplatin 40 mg/m2 weekly

M*

5

Carboplatin AUC2 weekly

M*

Carboplatin AUC2 + paclitaxel weekly

M*

Cetuximab weekly
Cetuximab + docetaxel 15 mg/m weekly

SOR

M

No systemic therapy

2

SOE

Notes: Rating: A-Usually appropriate; M-May be appropriate; U-Usually not appropriate. Disagreement, that is, the variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation (see narrative text). When there was disagreement, the group median rating was set automatically to 5. Strength of Evidence: S-Strong; M-Moderate; L-Limited; EC-Expert
consensus; EO-Expert opinion. Strength of Recommendation: " Strong Recommendation; # Weak Recommendation; — Additional considerations do not strengthen or weaken the panel's recommendation.
a
Conventional fractionation refers to 1.8 to 2.0 Gy.

The regular use of PORT for resected stage III/IV
SCCHN is based on both retrospective and prospective studies. These demonstrated worse local-regional control after
surgery alone or after PORT, for patients with pathologic risk
factors for recurrence, compared to patients without risk factors. Individual pathologic risk factors for recurrence
include: T3 or T4 tumors, multiple involved nodes,
lymphovascular invasion, anatomic location (eg, oral cavity
vs oropharynx), low neck location of lymph nodes,
extranodal extension (ENE), perineural invasion, and close/
positive margins.42,46,55,64,65,85,116 An increasing number of
risk factors is associated with an increased risk of
recurrence.31,46
Additional risk factors for recurrence identified in retrospective studies that are not regularly incorporated as selection criteria in prospective studies of PORT or chemoPORT include poorly differentiated tumors117,118 and, for
oral cavity cancers, depth of invasion (DOI).4,5 The AJCC8th edition staging incorporated DOI in the staging for oral
cavity cancers in recognition of its prognostic significance.

4.2 | Radiation therapy-sequence and
timing
PORT is typically preferred over preoperative RT. This
practice reflects results of clinical trials. A randomized
trial, RTOG 7303, demonstrated an improvement in
local-regional control (LRC) for patients treated with
60 Gy postoperatively compared to 50 Gy preoperatively
(LRC, 65% vs 48%, P = .04).42,55 Another study of
patients with resected hypopharynx SCCHN compared
PORT to preoperative RT using 55 Gy in each arm. The
study was stopped early due to an unexpectedly high
rate of postoperative deaths in the preoperative RT arm.
Additionally, the 5-year OS was better in the PORT
group (5-year OS 56% vs 20%, P < .10—no other P-value
given).56
Timely initiation and completion of PORT are important for optimal LRC and OS.21,31,46,51,81 There are several
metrics for the optimal initiation and duration of postoperative therapy.21 These include time from diagnosis to

Arms

Observation vs PORT

Mishra (India)45

Awwad (Egypt)34

Awwad (Egypt)33

Ang (USA)31

Accelerated hyperfractionation
(AHF)
vs
conventional fractionation (CF)

Accelerated hyperfractionation
(AHF)
vs
conventional fractionation (CF)

Adjuvant treatment by pathologic
risk stratification.
Low risk: no PORT
Intermediate: PORT
High-risk: PORT vs accelerated
PORT

PORT timing, dose, and fractionation

Observation
vs
PORT

Kokal (USA)41

70
OC, LX, HPX
T2/N1-2N2 or T3-4/any N
48% “inadequate margin”

56
OPX, OC, LX, HPX, Nodal
metastases
T3/4, N0-2 postoperative.
31% “inadequate margin”
Fresh tissue labeled with in vitro
3H-thymidine labeling index
(TLI) as marker of fast vs
slower growing tumors.

213,
OC, OPX, LX, HPX
Stage III (48%), Stage IV(38%)
ECE in 49%
Risk group definition:
Low risk: no RF; intermediate
risk = 1 RF other than ECE:
high-risk = ECE or ≥2 risk
factors.
Risk factors:
ECE, >1 nodal group, ≥2positive
nodes >3 cm node, OC site,
microscopic +margin and PNI.

140,
OC (all buccal)
Stage III/IV

51,
OC, Pharynx, Lx
Stage III/IV

Patients (N)
Sites
Stage
Definition of risk
(if applicable)

1995 to 1997.
AHF: 3 fractions per day at
1.4 Gy/fraction to 46.2 Gy/33
fractions in 12 d. 6 d per week
CF: 60 Gy in 30 fx in 6 wk, 5 d a
week.

1987 to 1989.
AHF: 42 Gy/30 F/11 d (3 F/d,
interval 4 h)
CF: conventional
50 Gy/25 F/5 wk
All with telecobalt.
Chemo: none

1991 to 1995
Low risk: no PORT
Intermediate risk: 57.6 Gy in 32 f
over 6.5 wk
High risk: 63 Gy in 1.8 Gy/f over
7 wk vs 63 Gy 1.8 Gy/d × 3 wk
then 2 fractions per day for last
2 wk (5 wk total)

1990 to 1994
RT: cobalt-60, mean dose of
60 Gy

1981 to 1984
RT was 50 Gy

Regimen details

Years accrued

NR

NR

59 months.

NR

30.3 mo

Median f/u

3-y LRC was significantly better in the
accelerated hyperfractionation (88 + 4%) than
in the CF (57 + 9%) group, P = .01. NSD in
OS
Late normal tissue reactions were worse in AFX
group (either significant or “trend.”) Overall
treatment time (time between surgery and the
end of radiotherapy) longer than 10 wk had a
significantly unfavorable effect on the LRC
for all patients.) (P = .005)

NSD in 3-y DFS (39% ± 9% CF vs 54% ± 10%
AHF) or OS (36% ± 9% CF vs 54% ± 10%
AHF).
Higher late complications in CFX arm (87% vs
63%).
AHF associated with a significant DFS benefit in
faster growing tumors (especially for TLI
10.4% corresponding to Tpot of <4.5 d). No
benefit to AHF for slower growing tumors.

Patients with low or intermediate risks had
higher LRC and OS than those with high-risk
features (P = .003 and P = .0001,
respectively), despite receiving no PORT or
lower dose PORT.
For high-risk patients, there was a trend toward
higher LRC and OS when PORT was
delivered in 5 rather than 7 wk.
Prolonged interval between surgery and PORT
in the 7-week schedule was associated with
lower LRC (P = .03) and OS (P = .01).

DFS improved with PORT 38% and 68%
(P < .005).

Decreased “overall recurrence rate” in PORT
arm (55.6% vs 36.5%, P = “NS”)

Results

Randomized trials evaluating oncologic outcomes after postoperative therapy for resected squamous cell carcinoma of the head and neck (N = 24)

Observation vs postoperative RT (PORT)

First author
(country)

TABLE 4

2

2

1

2

22

LOE
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Stratified by risk factors and
randomized:
Lower risk group: 57.6 vs 63 Gy
Higher risk group:
63 vs 68.4 Gy, all at 1.8 Gy per
fraction.

Conventional
fractionation (CF)
vs
accelerated fractionation (AF)

Peters (USA)46
Update: Rosenthal50

Sanguinetti (Italy)51

Arms

Preoperative RT
vs
PORT

42

(Continued)

Kramer (USA)
RTOG 73-03
10 y update: Tupchong55

First author
(country)

TABLE 4

226,
OC, OPX, HPX, Lx
Stage III: 9.3%
Stage IV: 87.6%
Patients with at least 1 high-risk
feature: pT4, positive margin,
pN >1, perineural/
lymphovascular invasion,
ENE, subglottic extension

240
OC, OPX, HPX, LX
T3/4:72%
Very few early stage pts with risk
factors:
T1: 5 pts
T2: 42 pts (26 T2N+)
Risk group based on a pointsystem.
Patients' primary sites and
involved necks were
independently assigned to
higher- or lower-risk categories
based on a cumulative point
score representing increasing
risk of recurrence.

277
OC, OPX, SGL or HPX
Stage III/IV: >85%

Patients (N)
Sites
Stage
Definition of risk
(if applicable)

1994 to 2000
CF: 2 Gy fraction per day (60 Gy
in 6 wk)
AF: (64 Gy in 5 wk) with a
biphasic concomitant boost
delivered during the first and
last weeks of treatment.

1983 to 1991.
RT: Cobalt. 54 Gy given
surgically undisturbed sites of
potential disease; 57.6 Gy to
pathologically uninvolved
parts of surgical bed, including
dissected region with negative
nodes.
Lower risk: 57.6 Gy vs 63 Gy
(1.8 Gy/d)
Higher risk: 63 Gy vs 68.4 Gy
(1.8 Gy/d)
Note: lower risk group initially
was 52.2 to 54 Gy but due to
early recurrences, minimal
dose was changed to 57.6 Gy.

1973 to 1979
SGL/HPX: 2 arms randomized to
preoperative 50 Gy or
postoperative 60 Gy
OC/OPX: 3 arms randomized to
preoperative 50 Gy or
postoperative 60 Gy or
definitive RT 65 to 70 Gy w
surgery for salvage if residual
at 6 wk post RT.
RT dose: preoperative RT (50 Gy)
or postoperative RT (60 Gy)

Regimen details

Years accrued

30.6 months.

>20 y

10 y

Median f/u

(Continues)

2

1

Patients who received a dose of ≤54 Gy had a
higher primary failure rate than those
receiving ≥57.6 Gy (P = .02). For patients
with ECE, recurrence was higher at 57.6 than
63 Gy or more.
The long-term report clarified that for low-risk
patients 57.6 Gy was sufficient. For high risk
patients, doses >63 Gy did not have a SS
benefit (they did not receive lower than
63 Gy).
Two or more of the following risk factors were
associated with an increased risk of
recurrence: oral cavity primary, mucosal
margins close or positive, nerve invasion, ≥2
positive lymph nodes, largest node >3 cm,
treatment delay greater than 6 wk,
and ≥ Zubrod performance status 2.
Moderate to severe complications of combined
treatment occurred in 7.1% of patients; these
were more frequent in patients who received
>63 Gy.
NSD in 2-y LRC [80% ± 4% for CF, 78% ± 5% for
AF (P = .52)] or 2-y OS [67% ± 5% for CF,
64% ± 5% for AF (P = .84)].
Trend for improved LRC for patients who had a
delay in starting RT (≥6.9 wk) and were
treated with AF compared with CF
(HR = 0.5, 95% CI 0.2-1.1).

1

LOE

RC was significantly better for PORT patients
than for preoperative RT patients (P = .04),
but absolute survival was not affected
(P = .15). 31% (18/58) of preoperative patients
failed locally within 2 y vs 18% (11/60) in
surgery + PORT group.
After 2 y, distant metastases and second
primaries were main failure types,
particularly in surgery + PORT group.

Results
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PORT
vs
PORT + weekly carboplatin
100 mg/m2

PORT
vs
PORT + weekly cisplatin
50 mg/m2

Argiris (USA)32

Bachaud (France)35

Addition of concurrent chemotherapy to PORT

Preoperative RT
vs
PORT

Vandenbrouck (France)56

Arms

Conventional fractionation CF)
vs
accelerated fractionation (AF)

(Continued)

Suwinski (Poland)54

First author
(country)

TABLE 4

83,
OC OPX, LX, HPX, CUP
Stage III/IV
All with ECE

76,
OC, OPX, HPX, LX
Stage IV 92%
All high-risk
High-risk features: ECE (75%) or
+ margin (0.5 mm or less),
LVI, PNI, ≥3 + LN

49,
HPX
Stage III/IV (74%)

279,
OC, OPX: 121
LX: 158
Median time from surgery to RT
was 9 wk.
Risk group based on MDACC
described in Peters et al46
High-risk patients: score of ≥3 at
primary site and/or neck. In
brief, score of 3 for neck would
be any ENE, 2 or more
involved nodes, grade 3 tumor
and a positive node. For
primary site score of 3 would
be non-larynx site except
T1N0, microscopic positive
margin, or a combination of
LVI, grade 3 tumor, + <5 mm
margin.

Patients (N)
Sites
Stage
Definition of risk
(if applicable)

1984 to 1988
RT: All Cobalt-60
Cisplatin: weekly 50 mg/m2
(7-9 cycles)

1994 to 2002
RT: 59.4 Gy/1.8 Gy/fraction,
50.4 Gy to clinically
uninvolved.
Carboplatin: 6 cycles

1967 to 1969
RT: preoperative was 5500 cGy
over 5.5 wk; postoperative was
5500 cGy over 6 wk with
interval to start less than 4 wk
postoperative.

2001 to 2004
No chemotherapy
RT: 3D-RT with parallel opposed
fields: adjuvant
CF: 63 Gy in 35 fractions of
1.8 Gy given 5 d per week
AF: same RT but given 7 d a
week (postoperative
continuous accelerated
irradiation: p-CAIR).
45 to 50 Gy in 25 fractions given
to the elective areas
(undissected areas and
dissected pathologically
negative).

Regimen details

Years accrued
Median f/u

NR

5.3 y

48 months.

Results

Improved OS in chemo-PORT group (P < .01).
The RT group displayed a higher rate of LRF
compared to chemotherapy group (41 vs 23%;
P = .08). Survival without LRF was better in
the chemotherapy group, the difference being
close to the level of significance (P = .05).

No statistically significant differences in DFS
(HR 0.82, P = .60) or OS (HR 0.90, P = .73).
The 2-y DFS (primary endpoint) was 58%
(95% CI 39%-76%) in arm A (radiation alone)
vs 71% (95% CI, 56%- 88%) in arm B (radiation
and carboplatin). Terminated early due to
slow accrual.

Trial stopped early due to unexpected high rate
of postoperative deaths in patients who
received preoperative RT.
PORT improved OS (56% vs 20%, P < .01)

Actuarial 3-y LRC was 64% vs 70% for CF and pCAIR (P = .32).
Subset analysis demonstrated significant
improvement of 3-y LRC in patients with
OPX/OC tumors receiving p-CAIR vs CF (74%
vs 53%, P = .02). No improvement in LRC for
Lx patients (P = .46).
Acute/late toxicity was acceptable, although
more patients had confluent mucositis with pCAIR (60% vs 33%).
Limit: ENE not routinely reported
(approximately 30% unknown ENE status),
delay in RT start (approximately 50% >9 wk
from surgery to RT), lack of systemic
radiosensitizer

LOE
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PORT + cisplatin 30 mg/m2
weekly
vs
PORT + cisplatin 100 mg/m2
every 3 wk

PORT
vs
PORT + cisplatin 100 mg/m2

Cooper (USA)38
Update:
Cooper39

Noronha (India)19

PORT
vs
PORT + cisplatin 100 mg/m2

Bernier (Europe)37

Arms

PORT
vs
PORT + cisplatin 35 to 40 mg/m2
weekly

(Continued)

Bandyopadhyay (India)36

First author
(country)

TABLE 4

N = 300
Stage III/IV
OC, OPX, HPX, LX, CUP
90% ENE
Adjuvant therapy in 93% (7%
were definitive)
If adjuvant, patients had ≥1 of:
ENE, ≤5 mm margin or
positive margin, more than 2
positive lymph nodes, T4
primary

459
OC, OPX, HPX, LX
High risk defined as ≥1 factor: 2
or more involved nodes, ECE,
microscopically involved
mucosal margins (n = 73,
18%).

334,
OC, OPX, HPX, LX
Stage III/IV
ENE 57%
High-risk defined as: pT3 or pT4
and any N-stage except pT3N0
larynx with negative margins;
T1-2N2-3; T1-2N0-01 with ≥1:
ENE, positive margins, PNI, or
vascular tumor embolism; or
OC/OPX with nodes at level IV
or V.

54, OC
All had high-risk factors defined
as: Stage III or IV
(n = 43,80%), 2 or more +LN,
ECE, PNI or LVI, positive
margin (n = 8, 15%), level
IV/V involvement.

Patients (N)
Sites
Stage
Definition of risk
(if applicable)

2013 to 2017
RT: 60 Gy for adjuvant to high
risk areas (tumor bed and
involved nodal area). Cobalt or
2D (conventional simulator)

1995 to 2000
PORT was 60 to 66 Gy in 30 to 33
fractions over a period of 6 to
6.6 wk.
Cisplatin: 100 mg/m2 q3
wk × 3 cycles

1994 to 2000
RT: 66 Gy over 6 1/2 wk
Cisplatin 100 mg/m2 on days 1,
22, and 43

2006 to 2008
PORT (60 Gy/30 F/6 wk)

Regimen details

Years accrued
Median f/u

22 mo

45.9 mo

60 mo

47 mo

Results

LOE

1

1

1

2

(Continues)

2-y LRC 58.5% in once a week vs 73.1% in every3-week arm (P = .14). Acute grade 3 or higher
71.6% in once-a-week vs 84.6% in once-every3-wk (P = .006)

Improved LRC in chemo-PORT group than in
the PORT-alone group (HR for local or
regional recurrence, 0.61; 95% CI, 0.41 to 0.91;
P = .01).
OS did not reach statistical significance in initial
report and with longer follow-up (HR for
death, 0.84; 95% CI, 0.65 to 1.09; P = .19).
The incidence of acute adverse effects of grade 3
or greater was 34% in the RT group and 77%
in the combined-therapy group (P < .001).

PFS higher in the chemo-PORT vs PORT (HR
0.75; 95% CI, 0.56 to 0.99, P = .04), with 5-y
PFS of 47% and 36%, respectively.
The OS higher in chemo-PORT group p (P = .02
by the log-rank test; HR for death, 0.70; 95%
CI, 0.52 to 0.95).
Severe (grade 3 or higher) adverse effects were
more frequent after combined therapy (41%)
than after RT (21%, P = .001).

LRC 51.4% with chemo-PORT vs 35.6% in PORT
(P = .39). 5-y OS 56.4% in CRT vs 51.3%
PORT with significant increase in grade 3-4
toxicity.

MARGALIT ET AL.
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PORT + cetuximab + cisplatin
30 mg/m2 vs
PORT + cetuximab + docetaxel
15 mg/m2

Induction cisplatin
+ bleomycin × 1 cycle
followed by S + PORT vs
induction cisplatin and
bleomycin followed by S
+ PORT and adjuvant monthly
cisplatin 80 mg/m2 × 6 mo vs
PORT

No postoperative chemotherapy
vs
Postoperative levamisole and
UFT (uracil/tegafur)

Harari (USA)40

Head and Neck Contracts
Program Study, National
Cancer Institute (USA)53

Lam (Hong Kong)43

Adjuvant chemotherapy regimens

PORT
vs
PORT + mitomycin C and
bleomycin

Smid52 (Slovenia)
Update: Zakotnik57

Arms

PORT
vs
PORT + carboplatin 50 mg/m2
twice weekly

(Continued)

Racadot (France)47

First author
(country)

TABLE 4

65
OC, OPX, HPX, LX
Stage III/IV

462
OC, LX, HPX
Stage III/IV
Stage II pyriform sinus

238,
OC, OPX, HPX, LX
Stage III/IV
All patients had ≥1: Positive
margins and/or ENE and/or
two or more nodal metastases.

114,
OC, OPX, HPX, LX, NC, PNS
Stage III/IV
ENE 53%
59% ≥1 high-risk factor
High-risk factors: ENE, PNI, LVI,
microscopic or macroscopic
residual disease).

144,
OPX, HPX, LX
Patients: Resected node positive
with or without ECE.

Patients (N)
Sites
Stage
Definition of risk
(if applicable)

1993 to 1995
Not clear how chemotherapy
sequenced with PORT
(majority received PORT)

1978 to 1982
RT: during week 3 or 4 after
surgery. 60 Gy in 5 to 5.5 wk
for clear margins. 60 Gy for
microscopic residual or close
margins (<0.5 cm on
permanent), positive frozen
followed by re-excision or
ENE. 70 Gy to gross residual.

2004 to 2006

1997 to 2001
Total RT dose (56-70 Gy).

1994 to 2002
PORT (54-72 Gy, 30-40 fractions,
6-8 wk) ± concomitant
Carboplatin (50 mg/m2
administered by IV infusion
twice weekly × 6 wk).

Regimen details

Years accrued
Median f/u

Results

A non-statistically significant difference in DM
(10% chemo vs 32% no chemo, P = .06) and
5-y DFS (57% with chemo and 39% without).

While OS and DFS were NS different between 3
groups, adjuvant chemotherapy group had a
lower rate of distant relapse (P < .03).

61 mo

30 mo

Delivery of chemo-PORT and cetuximab is
feasible and tolerated. 2-y OS was 69% for the
cisplatin arm and 79% for the docetaxel arm;
2-y DFS was 57% and 66%, respectively. Grade
3 to 4 myelosuppression was observed in 28%
of patients in the cisplatin arm and 14% in the
docetaxel arm; mucositis was observed in 56%
and 54%, respectively.

At 5-y in the PORT and postoperative CRT
arms, LRC was 65% and 88% (P = .03), DFS
33% and 53% (P = .04), and OS 37% and 55%
(P = .09).
On planned subgroup analysis, benefit of
chemotherapy appeared restricted to those
with high-risk factors.

2-y rate of LRC was 73% (95% CI: 0.61-0.84) in
the combined treatment group and 68% (95%
CI: 0.57-0.80) in the radiotherapy group
(P = .26). OS did not differ significantly
between groups (HR, 1.05; 95% CI: 0.69-1.60;
P = .81)
Stopped early due to publication of preliminary
results of EORTC.

4.4 y

32.2 mo,
Update: 76 mo

106 mo

LOE
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PORT or PORT and adjuvant
MTX.

Rentschler (USA)49
60
Lx, OC, OPX, HPX, NPX
Stage III/IV

135,
OC (alveolobuccal)
Stage III/IV

448,
OC/OPX/LX: stage III/IV
HPX: Stage II
High risk if ENE, margins
<5 mm or CIS at margins.
Low risk: no ENE and margins
≥5 mm

Patients (N)
Sites
Stage
Definition of risk
(if applicable)

1979 to 1983
All received surgery and PORT. 5
taken off due to unresectable
disease at surgery.
MTX dose-escalated from 40 mg/
m2 and escalated 10 mg/m2
weekly. Given as 4 doses
preoperative, 4 doses
postoperative pre-RT and 8
doses post-RT.

1987 to 1989
No patients received RT

1985 to 1990.
PORT dose risk-stratified based
on pathology:
low risk: 50 Gy/25 F
high risk: additional 10 Gy to
high risk region.
RT was 1.8-2.0 Gy/d
Chemotherapy: cisplatin 100 mg/
m2 on d1and 5-FU 1 g/m2 24hr
infusion d1-5 q 21 d for
3 cycles

Regimen details

Years accrued

43 mo

Minimum
12 mo.
(median
NR)

45.7 mo

Median f/u

Closed due to slow accrual. Median peak MTX
dose was 80 mg/m2. No statistically
significant difference in actuarial DFS
(P = 1.0) or OS (P = .61). Although patients
on the MTX arm appeared to have less local
and regional recurrences at first recurrence
(thus more distant metastases), this did not
reach statistical significance (P = .06). There
was NSD between the sites of recurrence at
death or last follow-up (P = .38).

DFS of 71% in the MTX arm vs 45% in the
control arm, (P < .01) with improved LC at
primary site in MTX arm (P < .01)

The 4-y OS was 44% in the RT arm and 48% in
the CT/RT arm (P = n.s.). 4-y DFS was 38% in
the RT arm compared to 46% in the CT/RT
arm (P = n.s.). At 4 y the local/regional
failure rate was 29% vs 26% for the RT and
CT/RT arms, respectively (P = n.s.). The
incidence of first failure in the neck nodes
was 10% on the RT arm compared to 5% on
the CT/RT arm (P = .03 without adjusting for
multiple testing) and the overall incidence of
distant metastases was 23% on the RT arm
compared to 15% on the CT/RT arm (P = .03).
“Risk group” status was a significant risk factor
for LRC.

Results

3

2

1

LOE

Abbreviations: Key: 5-FU, fluorouracil; AF, accelerated fractionation; CF, conventional fractionation; CI, confidence interval; CRT, chemoradiation; CUP, carcinoma of unknown primary
site; DFS, disease-free survival; DSS, disease-specific survival; DM, distant metastases; EBRT, external beam radiation therapy; ECS, extracapsular spread; ENE, extranodal spread; HNSCC,
head and neck squamous cell carcinoma; HPX, hypopharynx; HR, hazard ratio; LOE, level of evidence; LRC, local-regional control; LX, larynx; LVI, lymphovascular invasion; MTX, methotrexate; NC, nasal cavity; NPX, nasopharynx; NR, not reported; NSD, no significant difference; OC, oral cavity; OPX, oropharynx; OS, overall survival; PNI, perineural invasion; PNS, paranasal
sinus; PORT, postoperative radiation therapy; QOL, quality of life; RCT, randomized controlled trial; RFS, recurrence-free survival; RT, radiation therapy; S, surgery; SCC, squamous cell carcinoma; TORS, transoral robotic surgery.

Observation without PORT vs
MTX on postoperative day 3, 10,
17.

Rao (India)48

Arms

PORT alone
vs
3 cycles of adjuvant cisplatin/5FU
followed by PORT

44

(Continued)

Laramore (USA)
Aka INT 0034/RTOG 85-03)

First author
(country)

TABLE 4
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treatment initiation (DTI),21 surgery to PORTinitiation,21,31,46,81 and surgery to end of PORT.21,31 In
general, a ≤6-week interval from surgery to starting PORT
is optimal. This metric is derived principally from studies
of patients treated with radiation alone, yet retrospective
studies suggest that timely initiation of adjuvant radiation
is also associated with better OS amongst cohorts treated
with chemoPORT.21 For patients treated with PORT
alone, accelerated radiation may improve LRC for
patients who had a delay in starting RT as compared to
conventional fractionation.51,54

4.3 | PORT dose and fractionation
One RCT evaluated radiation dose amongst patients
stratified by pathologic risk factors for recurrence46 for
patients with stage III/IV SCCHN treated with PORT
without chemotherapy. Doses of ≤54 Gy, given in 1.8 Gy
fractions, to the primary site and/or pathologically
involved neck were associated with higher local-regional
relapse rates (LRR). There was no significant dose
response detected above 57.6 Gy except for patients with
ENE in the neck who had improved LRR at doses
≥63 Gy.46,50 A range of conventionally fractionated doses
were used in prospective phase II and III clinical trials.
In general, the high-risk region of the postoperative bed
was given 60 to 66 Gy in 1.8 to 2.0 Gy per fraction, the
higher dose given for concerns regarding margin-status
or ENE. Lower doses ranging from 46 to 54 Gy in 1.8 to
2.0 Gy were generally given to electively treated regions.
Simultaneous integrated boosts, or “dose-painting”
are frequently used with IMRT resulting in lower fraction
sizes of <1.8 Gy to a low-risk elective nodal coverage.
Prospective clinical trials should analyze the frequency of
in-field regional failures when treated at such low-dose
fraction sizes to determine the impact of “dose-migration” to lower fraction sizes with the common use of
IMRT dose-painting.
The MARCH meta-analysis of both definitive and
postoperative patients showed that altered fractionation
improved OS and secondary endpoints of progression-free
survival (PFS) and LRC. While all forms of altered fractionation improved local control, only hyperfractionation
improved OS compared to conventional fractionation.23
However, in a subsequent meta-analysis restricted to
postoperative randomized trials (n = 6), there was no
improvement in OS, PFS, or LRC with postoperative accelerated fractionation compared to conventional fractionation.24
The study was limited by the heterogeneity in accelerated
fractionation regimens of the RCTs and a smaller population, reducing the ability to identify potential subgroups that
may benefit most from accelerated regimens.

MARGALIT ET AL.

Even though individual RCTs have not demonstrated
an OS benefit33,34,51 with postoperative accelerated fractionation, some have shown a DFS or LRC benefit in specific subgroups such as those with stage III/IV tumors
and a prolonged interval from surgery to RT51; rapidly
proliferating tumors33,34; or oropharynx/oral cavity
tumors.54 A RCT from Poland compared 7 days a week
accelerated fractionation (“P-CAIR” postoperativecontinuous accelerated irradiation) with conventional
fraction given 5 days a week using 1.8 Gy per day to
63 Gy. There was no benefit to accelerated fractionation
in the total population and the rate of acute mucositis
was doubled. There was, however, a LRC benefit in the
oral cavity and oropharynx subgroup (74% p-CAIR vs 53%
CF, P = .02) in a population with a long median time from
surgery to PORT of 9 weeks.54 A post hoc analysis stratified by HPV-status showed 100% 5-year LRC for HPVpositive patients and no statistically significant difference
in outcomes for HPV-negative (5-year LRC 50.3% in CF vs
65.2% in p-CAIR, P = .37).91 The differential impact of
accelerated fractionation by HPV status further supports
the observation that improved risk-group stratification by
pathologic factors such as HPV-status can better determine which patients may benefit from intensification with
accelerated radiation (ie, HPV-negative tumors).
Single-arm prospective76,79,81 and randomized studies23,24,51 demonstrated that altered fractionation
increases acute toxicities, such as mucositis, dermatitis
and feeding-tube use during treatment. The effects on
late toxicity have varied, but at least one study showed an
increase in late toxicity.23,24,34

4.4 | Altered fractionation and
chemotherapy
In the definitive setting, the combination of chemotherapy and conventionally fractionated RT improved OS
compared to altered fractionation.23 In the postoperative
setting, there are limited data comparing postoperative
altered fractionation with or without chemotherapy.
The committee favors concurrent chemoradiation
schedules over altered fractionation regimens for
chemotherapy-eligible patients in view of the strength of
evidence for the addition of chemotherapy to conventional fractionation for high-risk patients.

4.5 | Radiation volume
Most clinical trials summarized in Tables 4 and S1 were
completed in the pre-IMRT era and describe techniques
treating the entire postoperative bed and, with some
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exceptions such as smaller lateralized buccal/alveolar
ridge tumors, treating both sides of the neck to elective
doses with higher dose to involved regions.
Reducing the volume of irradiated tissue decreases
acute and late toxicity. This was shown in two phase II
studies that reduced radiation dose and/or volume to the
pathologically negative neck or margin-negative primary
site; both demonstrated good LRC compared to historical
controls.15,70 The first prospective phase II study eliminated
radiation from the surgically treated pathologically nodenegative neck in a cohort of patients with Stage III/IV
SCCHN of whom 47% also received concurrent chemotherapy. At a median follow-up of 53 months, there were no
isolated recurrences in the un-irradiated surgically-treated
neck.15 The other phase II study was the AVOID trial from
the University of Pennsylvania. They omitted radiation to
the resected primary site of 60 patients with at ≥2 mm margins after TORS and no lymphovascular or perineural invasion. The 2-year local recurrence free survival was 97.9% at
2.4-year follow-up.18 While there may be an impact of systemic therapy on potential microscopic disease in the unirradiated neck, existing studies have not demonstrated a
role for systemic therapy in treating the unirradiated neck.
In the absence of PORT, adjuvant chemotherapy (methotrexate) improved disease-free survival (DFS) by reducing
local recurrence in a population of resected alveolobuccal
HNSCC,49 supporting the concept that postoperative chemotherapy may have an effect on local-regional microscopic
disease in some cases of resected SCCHN. Currently there is
no demonstrated role for chemotherapy as a substitute for
PORT when there are pathologic risk factors for recurrence.

4.6 | Role of proton therapy
The role of postoperative proton therapy currently is not
well-defined and has not been compared in a randomized
clinical trial to standard photon PORT delivered using
IMRT and IGRT (Image Guided Radiation Therapy). Dosimetric studies suggest that with appropriate treatmentplanning a reduction in dose to normal tissue, such as the
mucosa of the oral cavity (for non-oral-cavity cancers),
may translate into reduced mucositis and dry mouth.119 At
present, there is insufficient published evidence of either
improved local control or decreased morbidity to recommend postoperative proton therapy for resected SCCHN.

4.7 | Addition of chemotherapy to PORT
Suboptimal outcomes with PORT alone served as the
impetus to study the addition of chemotherapy to PORT
in phase II59 and randomized phase III clinical
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trials,19,32,35,38,43,47,52,57 also summarized in systematic
reviews and meta-analyses.20,26,29,30
Early single-arm prospective clinical trials evaluated the
optimal sequencing of postoperative chemotherapy before
or after PORT.64,65 Randomized trials compared PORT
alone to either postoperative chemotherapy before PORT44
or after PORT.49,53 None showed a statistically significant
improvement in OS or LRC, yet two trials showed a statistically significant reduction in DM with the addition of three
cycles of postoperative cisplatin and 5FU given before
PORT44 or six cycles of maintenance monthly cisplatin
80 mg/m2 after PORT.53 Subsequent clinical trials studied
the benefit of concurrent chemotherapy with PORT.
PORT and cisplatin: Two large randomized controlled
trials, Radiation Therapy Oncology Group (RTOG) 9501
and the European Organization Research and Treatment
of Cancer (EORTC) 22 931 demonstrated a statistically
significant LRC benefit with the addition of cisplatin
100 mg/m2 to PORT, given every 3 weeks for three
cycles37,38 for patients with “high-risk” features. A statistically significant OS improvement was shown in the
EORTC study.37 In RTOG 9501, while the difference in
3-year OS was 56% vs 47% (P = .09), a statistically significant OS improvement was not demonstrated in long-term
follow-up.38,39 The trials had different definitions of
“high-risk” features. The EORTC trial enrolled patients
with tumor ≤5 mm from the surgical section margins,
ENE, involvement of lymph nodes at levels 4 or
5 from oral cavity or oropharynx cancer, perineural disease, and/or vascular embolism. The RTOG trial enrolled
high-risk patients with ENE, tumor at the surgical
section margins, or two or more involved lymph nodes.
The rate of grade ≥3 toxicity was more than doubled with
the addition of chemotherapy. The rate of DM did not
differ between arms. Subsequent single arm phase II
studies showed the regimen could be combined with a
postoperative accelerated weekly concomitant boost regimen74 and could be tolerated by populations outside of
North America and Europe, such as in Japan.67,73
Two trials compared weekly dosing of cisplatin with
PORT compared to PORT-alone in patients with stage
III/IV SCCHN.35,36 An OS benefit was demonstrated when
cisplatin 50 mg/m2 weekly was added to PORT for stage
III/IV SCCHN with extranodal extension; there was a nonstatistically significant improvement in LRC.35 A smaller
study with a wider definition of “high-risk” used weekly cisplatin at a lower dose of 35 to 40 mg/m2 and did not show a
statistically significant difference in OS or LRC.36
PORT and mitomycin-C (MMC): MMC and bleomycin
conferred a LRC and OS benefit when added to PORT for
resected stage III/IV SCCHN.52 A subsequent pooled
analysis showed MMC added to PORT improved LRC
and DFS but not OS or DM.86,90 This benefit persisted
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F I G U R E 1 Study selection
QUOROM flow diagram

Records identified through Ovid
MEDLINE ® and Embase® search:
(N=5689)

Records after duplicates removed: (N=5660)

Records screened using title and abstract
screening (N=5660)

Records Excluded
(N=5,469)

Full text articles excluded, with
reasons N=95
Full-text articles assessed for eligibility
(N=191)

Recommended by Panel
due to relevance and met
pre-defined literaturesearch eligibility criteria.
Studies published since
01/2019 cut-off (N=4)
Relevant RCT not
identified in search (N=1)

Details:
Not in English: 5
Not study population = 2
Not intervention of interest = 27
Not an included study design=54
Not an outcome of interest=1
Sample size <20 =6

Final studies included in qualitative synthesis
N=101
Details:
Systematic reviews=13
RCTs=29
Prospective phase I/II:22
Prospective cohort studies: 28
Post-hoc analyses of RCT: 9

with longer follow-up accompanied by an increase in late
toxicity such as hypothyroidism.57
PORT and carboplatin: Two RCTs showed no DFS or
OS benefit with the addition of carboplatin 50 mg/m2
twice weekly47 or 100 mg/m2 weekly32 to PORT in a population of stage III/IV resected SCCHN with high-risk
features. However, both studies closed prematurely prior
to completing the anticipated enrollment.
Other randomized studies: One prospective study of
postoperative levamisole and uracil/tegafur did not show
an OS or DFS benefit but did demonstrate a nonstatistically significant decrease in DM in the chemotherapy group (10% vs 32%, P = .06).43 In this study, approximately 78% of patients received PORT, but the timing of
chemotherapy in relation to PORT, whether concurrent
or otherwise, was not described.
A pooled analysis29 of the results from four randomized studies35,37,38,52 demonstrated a LRC benefit and OS
benefit with the addition of concurrent chemotherapy to
PORT. At least half of patients in each trial had ENE,
and they predominantly had T3 or T4 disease. Other systematic reviews and meta-analyses confirmed a benefit of
postoperative CRT, with a trade-off of increased acute

toxicity.26 The effect on late toxicity from the addition of
chemotherapy to PORT is not well-defined in prospective
studies. Several trials demonstrated LRC and/or OS benefits with the addition of chemotherapy to PORT, but none
of them confirmed a reduction in DM.37,38,52,57
A Cochrane review of chemotherapy for oral cavity
and oropharyngeal cancer concluded that postoperative
chemotherapy is associated with improved OS compared
to surgery with or without PORT and that this improvement may be greater with concurrent chemotherapy
compared to sequential therapy.20 This is consistent with
meta-analyses of definitive treatment, which show the
greatest benefit of chemotherapy when administered concurrently with radiation therapy.120

4.8 | Optimal concurrent chemotherapy
The majority of evidence supporting concurrent chemotherapy is with concurrent cisplatin, driven by the two
largest trials, RTOG 950138 and EORTC 22931.37
Reduced-dose three-weekly or weekly regimens were
explored to improve the tolerability beyond that three
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cycles of cisplatin 100 mg/m2.61 A systematic review and
meta-analysis compared every 3-week high-dose cisplatin
(100 mg/m2, three doses) to weekly lower-dose cisplatin
(≤50 mg/m2, ≥ six doses) included 11 clinical trials from
the postoperative setting; it showed no OS difference with
similar rates of compliance and slightly higher grade 3 to
4 dysphagia and weight loss with the weekly regimen.27
The review included a randomized trial of PORT with
either cisplatin 30 mg/m2 weekly or three-weekly cisplatin 100 mg/m2,19 confirming superior LRC (primary
endpoint) with three-weekly cisplatin. It is noteworthy
that the 30 mg/m2 is lower than the 40 mg/m2 commonly
employed in clinical practice and the 50 mg/m2 weekly
cisplatin dose that tested favorably in the RCT comparing
it to PORT-alone,35 discussed above. At the time of this
publication, the Japanese Clinical Oncology Group
(JCOG) 1008 trial has been published in abstract form
and showed non-inferiority of weekly cisplatin 40 mg/m2
to three-weekly cisplatin in high-risk patients with microscopically
positive
margin
and/or
extranodal
extension.121

4.8.1 | PORT combined with EGFRinhibition
While phase I and II studies have evaluated the feasibility
and efficacy of EGFR inhibition combined with PORT, it
has not been directly compared with cisplatin and PORT.
RTOG 0234 tested the addition of cetuximab to weekly cisplatin or weekly docetaxel with favorable results compared
to historical controls of the RTOG 9501 trial of PORT and
three-weekly cisplatin.38,40 The combination of PORT with
panitumumab and weekly cisplatin 30 mg/m2 was feasible
in a stage III/IV high-risk resected cohort.60 PORT combined with the irreversible EGFR/HER inhibitor, afatinib,
with or without docetaxel was not tolerated in an oral cavity cancer population.17 PORT with weekly cisplatin will
be directly compared to PORT with docetaxel and PORT
with docetaxel/cetuximab in the first phase of RTOG 1216.
The trial will reopen and include an arm of PORT and
weekly cisplatin with the checkpoint inhibitor,
atezolizumab, to be compared to PORT and cisplatin, and
PORT and docetaxel/cetuximab (NCT01810913).

4.8.2 | PORT and other chemotherapy
regimens
Additional published postoperative regimens were
focused on intensification and do not directly compare
PORT with concurrent chemotherapy.63,66,68,72,75,77,78
Studies have shown that PORT with or without
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chemotherapy therapy can be delivered after transoral resection with good oncologic outcomes.80,82

4.9 | Margins—Defining an optimal
margin
A “close” or microscopically positive margin is a traditional indication for PORT or chemoPORT, having been
used as an eligibility criterion for multiple prospective
clinical trials. There is controversy regarding the margin
sufficient to omit PORT, or to warrant intensification
with chemoPORT. One of the reasons for this is that margin status was defined differently in clinical trials. For
example, in RTOG 9501 a “high-risk” feature was a
microscopically positive margin. Yet in the EORTC study,
patients were considered “high-risk” for a close margin
defined as <5 mm.37,38 A large retrospective study of SCC
of the oral tongue (n = 381), of whom 25% received postoperative therapy, proposed redefining the cut-off for
close margin to ≤2.2 mm.122
While a microscopically positive margin is a clear
indication for postoperative therapy, the optimal cut-off
to consider a margin “negative” (not close), is still subject
to debate and may well be different for different primary
sites and p16-positive (HPV-mediated) oropharynx cancers (as opposed to p16-negative).
Further uncertainty has arisen in the context of transoral surgical management of oropharynx cancer where the
superior constrictor margin is typically no more than
2 mm, representing the average thickness of the constrictor
muscle. Current trials such as ECOG 3311 defined a negative margin at the deep constrictor as “no tumor on ink,”
highlighting the importance of careful intraoperative labeling to enable pathologists to interpret the location of the
margins such that the limited margin can be placed in anatomical context. Lastly, piece-meal resection or separately
submitted margins can make it challenging to quantify the
distance of tumor to the margin.
Brachytherapy: Postoperative brachytherapy is used
by some institutions to minimize off-target integral dose
to the adjacent tissue. There are few prospective studies
evaluating outcomes with postoperative brachytherapy
and none that compare brachytherapy boost to fullcourse external beam RT. Two prospective studies incorporated high-dose rate brachytherapy and EBRT demonstrating feasibility of the combination71,77; there were
increased severe complications in posteriorly located
implants compared to anterior implants.71 Even when
brachytherapy is given to the surgical bed, an R1 resection was associated with worse local control than an
R0 resection88; a brachytherapy boost should not be used
as a substitute for a margin-negative resection. The
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timing of brachytherapy (whether before postoperative
day five or after) did not seem to have a statistically significant impact on patients with newly diagnosed
SCCHN.89

5 | TOPIC 2 : SUMMARY OF
S T U D I E S WI T H QU A L I T Y O F L I F E
AND FUNCTION OUTCOMES
Monographs shown in Table S2 reported quality of life
and functional assessments after postoperative therapy.
Two systematic reviews summarized clinical studies with
questionnaire-based endpoints93 and observer-rated
speech and swallow functional assessments.92 A singlerandomized trial studied the effect of radiation to normal
tissue and observer-rated mucositis.94 The remaining
studies either included patient-questionnaire endpoints95-101,103-106,109,110,113,115 or observer-rated measurements of head and shoulder mobility,102 video
fluoroscopy and speech assessment using standardized
testing,107 lymphedema and fibrosis measurement,108 oral
bite force and masticatory function,111 tongue sensation
and mobility112 and maximal mouth opening.114

5.1 | Pretreatment factors and function
after postoperative therapy
Baseline patient and tumor-related factors prior to surgery are predictive of outcomes after resection and postoperative therapy. Patient-related factors include baseline
comorbidity,92 depression,98 socioeconomic status, and
advanced age.115 Tumor-related predictors of poor QOL
and functional outcomes include higher T-category,92
N-category,110 and tumor location.96 For example, one
prospective study of mostly locally advanced oral cavity
SCCHN patients showed worse patient reported QOL
outcomes for floor of mouth tumors relative to other
tumors including oral tongue, alveolar ridge, and hard
palate.96
Prior to postoperative therapy, patients can sustain
postsurgical changes (such as lymphedema and fibrosis)
that impact QOL and function108; altered mastication111;
reduced tongue mobility and sensation112; decreased
maximal mouth opening114; and shoulder dysfunction.113
Surgical factors associated with worse QOL and/or function include the extent of resection, the site of resection,
and the type of reconstruction or prostheses
required.92,93,96,104,109
Such postoperative changes should be considered as
baseline assessments in the course of clinical trials prior
to initiation of postoperative therapy. Posttreatment
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function and QOL reflect both surgical and postsurgical
treatments and may not solely be related to postoperative treatments.

6 | TOPIC 3: RESECTED EARLYSTAG E SCC HN
The role of PORT in stage I-II SCCHN is not welldefined; these patients are not well-represented in randomized trials (see Table 1 and 4). A small percentage of
patients with involved margins were included in studies
of PORT and/or chemo-PORT. An increased number of
adverse features (eg, perineural invasion, depth of invasion, margin status, lymphovascular invasion, poor differentiation, etc) is likely to influence the risk of recurrence
for patients with resected Stage I-II SCCHN,122 as
suggested by literature review. When there are uninvolved margins, the benefit of postoperative therapy for
patients with single risk factors such as perineural invasion28 or combinations thereof, is not well-defined.
Retrospective data show the importance of DOI as a
risk factor for LRR.4,5 As a result, recent studies, such
as RTOG 0920 (NCT00956007), which compare PORT to
PORT with cetuximab include depth of invasion (DOI) in
the eligibility criteria, specifically including AJCC-7 pT2
N0 oral cavity (OC) cancers >2 cm but ≤4 cm, with
>5 mm. There is insufficient prospective evidence to recommend regular application of PORT for patients with
OC tumors that are ≤4 cm but with >5 mm DOI.

7 | TOPIC 4 : R ESECTED LOCALLYADVANC ED S CC HN, NEGATIVE
M A R G I N S AN D N O E X T R A N O D A L
EXTENSION
Most patients included in prospective studies of postoperative therapy have pathologic stage III or IV cancers.
Even within the group of stage III-IV SCCHN, there
may be low-risk groups than may not require postoperative therapy. A systematic review of randomized and
non-randomized studies sought to determine the benefit
of PORT in patients with pT1-2 oropharynx cancer and
a single involved ipsilateral node ≤3 cm (AJCC-7
pN1).25 Due to the limitations and heterogeneity of existing data, the strength of evidence was considered low
for making recommendations for patients with
pT1-2 N1 oropharynx cancer with a single ipsilateral
node and no ENE with tumor-free resection margins.
There is also limited evidence to support use of PORT
for patients with a single lymph node >3 cm and ≤6 cm
(AJCC-7 N-category N2a).
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A post hoc subgroup analysis of two randomized trials
confirmed a LRC and OS benefit from adding chemotherapy to PORT for patients with microscopically positive
margins and ENE.78,84 Aside from the risk factors of positive microscopically involved margins and ENE, there is
uncertainty regarding risk factors that warrant the addition of chemotherapy to PORT. The absence of a statistically significant OS benefit in subgroups without ENE or
positive margins does not define lack of benefit. It may
have been related to lack of statistical power or relatively
smaller benefit than for patients who had the high-risk
features of ENE or positive margins. The decision to provide postoperative chemo-PORT should be made on a
case-by-case basis (Table 2B).

8 | T O P I C 5 : RE S E C T E D
P16-POSITIVE (HPV-MEDIATED)
SQUAMOUS CELL CARCINOMA OF
T H E OR O P H A R Y N X
To date, there are no published RCTs that compare deintensified to standard postoperative therapy.22 Single
arm studies show good oncologic outcomes of deintensified regimens compared to historical controls.16,18
A recent phase II study of 80 patients with HPV-mediated
oropharynx SCC showed a 2-year PFS and LRC of 91.1%
and 96.2%, respectively, with a postoperative regimen of
30 Gy given at 1.5 Gy twice daily with a simultaneous
integrated boost of 1.8 Gy BID to areas of ENE (total dose
36 Gy) and concurrent weekly docetaxel 15 mg/m2.16 The
ECOG 3311 phase II clinical trial has completed followup and will determine the efficacy of reduced- dose PORT
(50 Gy) compared to standard PORT (60 Gy) for patients
with intermediate-risk cancers, negative margins, and
≤1 mm extranodal extension (NCT01898494). At the time
of this publication, ECOG 3311 is published in abstract
form123 with a median follow-up of 31.8 months and suggests that 50 Gy may be sufficient for such patients. The
reduced dose arm will be carried forward into subsequent
phase III trials. Other large multi-institutional clinical trials are underway for postoperative de-intensification
studies for patients with favorable HPV-positive oropharynx, including PATHOS (NCT02215265) and ORATOR-II
(NCT03210103) amongst many other single-institutional
phase II trials. De-intensification of PORT should only be
undertaken in the course of clinical trial (Table 3).

8.1 | Summary of recommendations
• The committee strongly recommends that postoperative
therapy decisions be based on consideration of the factors
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•

•

•

•

•

•

•

•

that were used in the assignment of T- and N-categories
prior to the AJCC 8th edition as clinical trials that form
the basis of the above recommendations employed staging prior to the recent AJCC staging criteria.
The committee identified several areas of controversy
and subject for future research, as shown in the Clinical Variants (Tables 1-3) and mentioned below, where
there was insufficient agreement to provide a consensus recommendation.
The committee strongly recommends that it is usually
appropriate that postoperative radiation therapy
should be initiated within 6 weeks of surgery when
postoperative healing permits.
The committee strongly recommends that concurrent
systemic therapy is usually appropriate for relatively
“fit” patients who have microscopically involved surgical margins and/or extranodal extension.
The committee strongly recommends concurrent
cisplatin-based therapy as usually appropriate. Specifically, cisplatin 100 mg/m2, is recommended as usually
appropriate when concurrent therapy is indicated.
There is insufficient evidence comparing three-weekly
cisplatin 100 mg/m2 to weekly cisplatin at doses of at
least 40 mg/m2 weekly, which may be appropriate, to
support adoption of the latter schedule.
The committee strongly recommends that altered fractionation should be considered usually appropriate for
patients who are not medically eligible for chemotherapy but have risk factors that otherwise would warrant
the addition of chemotherapy. The committee
acknowledges that most studies showing the benefit of
altered fractionation were performed in the pre-IMRT
era. There is insufficient evidence to recommend a preferred altered fractionation regimen.
The committee strongly recommends postoperative
radiation therapy as usually appropriate for patients
with intermediate risk factors for recurrence, including
pT3-4 tumors, multiple involved nodes, or a single
node >6 cm.
The committee strongly recommends additional therapy
as usually appropriate for early-stage oral tongue cancer
with a positive margin. PORT-alone was strongly recommended as usually appropriate when re-excision is
not performed to clear the region of the close/positive
margin. Yet there was insufficient agreement on the
appropriateness of PORT to the primary-site only or
unilateral or bilateral neck irradiation. There was insufficient agreement on the role of concurrent systemic
therapy or altered fractionation for this situation.
The committee recommends PORT as usually appropriate
for early-stage oral tongue cancer with increased depth of
invasion (DOI); there is insufficient evidence to routinely
recommend PORT for a specific DOI. While agreement

20

was not reached on the appropriateness of unilateral or
bilateral nodal irradiation, the committee recommended
against PORT to the primary site only, which is usually
not appropriate for oral cavity cancer with increased DOI.
• The committee does not recommend de-escalation of
postoperative therapy, including reduced-dose PORT
or omission of chemotherapy for p16+ oropharynx
cancer, in routine clinical practice until additional
high-quality prospective data is available including
publication of ECOG 3311.
• Clinical studies that compare standard of care postoperative therapy to de-intensified therapy will be published
in the upcoming years and may change the above
recommendations.

8.2 | Summary of evidence
Studies with primary oncologic endpoints are shown in
the Table S1 and included 11 systematic reviews,20-30
24 randomized trials with four long-term updates,19,31-57
29 non-randomized clinical trials,15-18,58-82 and nine post
hoc analyses of randomized trials.83-91 The randomized trials are presented in Table 4. Studies that focused on nononcologic endpoints are shown in the Table S2 and
included two systematic reviews,92,93 one randomized
trial,94 and 21 non-randomized clinical trials.95-115 All studies reported staging prior to the implementation of AJCC-8.
The 101 references cited in the ARS Appropriate
Use Criteria Head and Neck Cancer Postoperative Management Evidence Table were published from 1977 to
2020. Of the 101 references, 78 are categorized as therapeutic references including 11 systematic reviews/metaanalyses, 10 well-designed studies, 31 good quality studies, 21 quality studies that may have design limitations,
and 1 of limited quality that may not be useful as primary evidence. Updates of randomized trials were
included in the grading of the initial trial publication.
There were 23 studies categorized as descriptive studies
including 2 systematic reviews and 20 quality nonrandomized prospective cohort studies and 1 study of
limited quality.
Although there are references that report on studies
with design limitations, 41 well-designed or good quality
studies provide good evidence.

8.3 | Supporting documents
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